Journal of Stem Cells and Tissue Engineering

Dr. Shailendra Dwivedi is an Associate Professor in the Department of Biochemistry at All India Institute of Medical Sciences (AIIMS), Gorakhpur, India. He holds a PhD in Biochemistry from King George Medical University, Lucknow, with specialized research in cytokine gene polymorphisms and cancer biology. Dr. Dwivedi is a renowned molecular medicine expert and Founding President of the Indian Society for Precision Medicine and Molecular Medicine (ISPMMM). His research spans cancer stem cells, precision medicine, microRNA biology, and regenerative medicine. He has published over 60 research articles and 16 international book chapters, and serves on the editorial boards of multiple peer-reviewed journals. His work significantly contributes to advancing cancer diagnostics, stem cell therapy, and molecular research.Dr. Shailendra Dwivedi is an Associate Professor in the Department of Biochemistry at All India Institute of Medical Sciences (AIIMS), Gorakhpur, India. He holds a PhD in Biochemistry from King George Medical University, Lucknow, with specialized research in cytokine gene polymorphisms and cancer biology. Dr. Dwivedi is a renowned molecular medicine expert and Founding President of the Indian Society for Precision Medicine and Molecular Medicine (ISPMMM). His research spans cancer stem cells, precision medicine, microRNA biology, and regenerative medicine. He has published over 60 research articles and 16 international book chapters, and serves on the editorial boards of multiple peer-reviewed journals. His work significantly contributes to advancing cancer diagnostics, stem cell therapy, and molecular research.

• Gene therapy and editing
• Cancer Stem Cells
• Regenerative Biology and Stem Cell Research
• Monkeypox and viral immunity

1.  Current Role: Associate Professor, Department of Biochemistry, AIIMS Gorakhpur (since July 2022).

2.  Leadership Roles:

a.  Founding President, Indian Society for Precision Medicine and Molecular Medicine (ISPMMM).

b.  Member, Research Advisory Boards, Human Ethics Committees, and Institutional Research Cells at AIIMS.

3.  Major Projects:

a.  Principal Investigator:

i. Evaluation of immune status of antigen-presenting proteins, checkpoint inhibitors, and regulating miRNAs in Triple Negative Breast Cancer (ICMR MRU-2023).

ii. Personalized immunotherapy exploration in chemo-resistant Triple-Negative Breast Carcinoma (UPCST 2025).

iii. Epigenetic and non-coding RNA regulation of TAP1 and TAP2 in oral and breast cancer (ICMR 2025).

b. Completed Projects:

i.  SERB-DST National Post-Doctoral Fellowship (2016–2020) on breast cancer stem cells and oncogenic miRNAs.

ii. IADVL-funded project (2021) on MITF and hormone status in melasma patients.

iii.  Multiple intramural projects on breast cancer, arsenic/fluoride exposure, diabetes, and miRNA regulation.

4.  Workshops & Conferences Organized:

a.  ISPMMMCON2025 – National Conference, Organizing Secretary.

b.  Molecular Biology Workshop (RNA isolation & gene expression), Chairperson, AIIMS Gorakhpur (2025).

5.  Editorial Work:

a.  Associate Editor, Indian Journal of Clinical Biochemistry (Springer, PubMed indexed).

b.  Editorial Board Member in 10+ journals including World Journal of Stem Cells, Clinical Cancer Drugs Journal, Exploratory Research and Hypothesis in Medicine, etc.

6.  Professional Memberships:

a.  ASCO, ACBI, EACR, NAMS (MAMS), Epidemiology Foundation of India, ISPMMM.

1. World Journal of Stem Cells (2022) – miRNA-21 and cancer stem cells in breast cancer.

2. Indian Journal of Clinical Biochemistry (2023) – Studies on oral cancer, miRNAs, inflammation, and environmental toxicology.

3. The Prostate (2015) – Genetic variability of IL-18 and IL-10 in prostate carcinoma.

4. Cytokine (2015) – Serum cytokine levels and genetic variability in prostate cancer.

5. Biomedical Research International (2014) – Pro- and anti-inflammatory markers in prostate carcinoma.

6. Andrology (2014) – Obesity and male fertility.

7. Growth Factors (2019) – Role of growth differentiation factor 15 in carcinogenesis.

8. EJIFCC (2024) – miRNAs in cancer: diagnostic and therapeutic perspectives.

9. Endocr Metab Immune Disord Drug Targets (2025) – TAP1/TAP2 downregulation in oral carcinoma.

10. Curr Gene Ther (2025) – Gene therapy and editing in molecular medicine.